Walmart halts H-1B visa offers amid Trump’s $100,000 fee increase - Bloomberg
Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics Inc (NASDAQ:LXEO), sold a total of 3,526 shares of common stock on October 17, 2025. The sales, executed in multiple transactions, generated $31,529. The transaction comes as the stock shows strong momentum, with InvestingPro data revealing a remarkable 253% return over the past six months and a current market capitalization of $473 million.
The price per share for the sales ranged from $8.53 to $9.59. Specifically, 3,486 shares were sold at a weighted average price of $8.935, and 40 shares were sold at a weighted average price of $9.561.
On October 15, Robertson also acquired 9,900 shares of Lexeo Therapeutics , Inc. common stock. These shares were acquired through a non-taxable transaction.
Following these transactions, Robertson directly owns 68,930 shares of Lexeo Therapeutics.
In other recent news, Lexeo Therapeutics announced a public offering and concurrent private placement, aiming for gross proceeds of approximately $135 million. The company has priced its public offering at $8.00 per share, offering 15,625,000 shares, with an option for underwriters to purchase an additional 2,343,750 shares. This development follows Lexeo’s announcement of additional LX2020 PKP2 data. In response to the public offering, Stifel has adjusted its price target for Lexeo Therapeutics from $20.00 to $18.00, though it maintains a Buy rating on the stock. Meanwhile, H.C. Wainwright has increased its price target to $15.00 from $9.00, citing positive feedback from the FDA regarding the company’s therapy. The FDA’s feedback included openness to a pooled Phase 1/2 and pivotal dataset and acceptance of an earlier LVMI assessment for accelerated approval. These recent developments are part of Lexeo’s ongoing efforts to advance its clinical-stage genetic medicine initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.